Compd with b-cyclodextrin
CHS pharmaceutical products company
National and provincial code:
The present invention relates to a preparation method of inclusion complex of piroxicam and β-cyclodextrin. In more detail, according to the method of the present invention, the aqueous solution of these two components is subjected to a freezing treatment at an extremely high speed before drying. The resulting product has more favorable physico-chemical characteristics as well as technological and biopharmaceutical properties than the products obtained according to the processes of the prior art. The resulting product is suitable for the preparation of a pharmaceutical composition for oral administration.
The gastric irritation of piroxicam β-Cyclodextrin Inclusion compound in rats and the dissolution rate and bioavailability of piroxicam β-Cyclodextrin Inclusion compound capsules in vitro were studied. The results showed that piroxicam made into β-Cyclodextrin Inclusion compound had less irritation than piroxicam raw material. After oral administration of piroxicam β-Cyclodextrin Inclusion Complex capsules and piroxicam ordinary tablets, the plasma concentration of piroxicam was determined by HPLC. The AUC of the amine capsule was 110% of the tablet by one-compartment model fitting, the absorption half-life T 1/2 (Kα) and peak T m were less than the tablet, and the results of in vitro dissolution experiments, capsule dissolution rate was significantly greater than the tablet is parallel.